Showing results (71-80 of 115) with videos related to
Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2021
Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional TrialMatthew J Frank, Nasheed M Hossain, Ali Bukhari, et al.Nature Medicine|April 19, 2011
B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodiesDaniel A Winer, Shawn Winer, Lei Shen, et al.Blood Cancer Discovery|December 18, 2025
Clinical and Cytokine Features of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like SyndromeHrishikesh K Srinagesh, Anne Marijn Kramer, John H Baird, et al.Journal of Immunology (Baltimore, Md. : 1950)|May 25, 2010
Individual variation in the germline Ig gene repertoire inferred from variable region gene rearrangementsScott D Boyd, Bruno A Gaëta, Katherine J Jackson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2025
Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical StudiesFrederick L Locke, Javier L Munoz, Michael T Tees, et al.Blood Advances|August 23, 2021
Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemiaLori Muffly, Vandana Sundaram, Connie Chen, et al.Lancet (London, England)|July 12, 2024
CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 studyMatthew J Frank, John H Baird, Anne Marijn Kramer, et al.Bone Marrow Transplantation|December 19, 2023
Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository studyPhilip L McCarthy, Kristopher M Attwood, Xiaojun Liu, et al.Blood|March 1, 2023
Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agentsMichael A Spinner, R A Sica, John S Tamaresis, et al.Blood Cancer Journal|October 9, 2024
Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myelomaSurbhi Sidana, Andriyana K Bankova, Hitomi Hosoya, et al.Pageof 12